Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor Generics Watch: FDA Has Yet To Approve ANDA For The World's #1 Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Mylan had pointed to June 28 as the earliest date FDA could approve atorvastatin ANDAs; the agency is continuing discussions with Ranbaxy about its exclusivity status.
Advertisement

Related Content

Can Watson Give Birth To A Pregnancy Franchise As It Helps Lay Lipitor To Rest?
Countdown To Generic Lipitor: Watson Expects Pfizer To Retain 40% Market Share For Six Months
Countdown To Generic Lipitor: Watson Expects Pfizer To Retain 40% Market Share For Six Months
Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty
India's Race For Lipitor: More Than Five Players May Blunt Generic Gains In Post-Exclusivity Period
Pfizer Keeps Teva's Generic Lipitor Out Of U.K. For Now; Wins Six Month Patent Extension
Pfizer Keeps Teva's Generic Lipitor Out Of U.K. For Now; Wins Six Month Patent Extension
Lipitor Generics: Questions About Mylan's ANDA Weigh Heavily In Court's Dismissal Of Lawsuit Against FDA
Mylan Lawsuit Seeks To Force FDA's Hand On Lipitor Generics
Mylan Lawsuit Seeks To Force FDA's Hand On Lipitor Generics

Topics

Advertisement
UsernamePublicRestriction

Register

PS072456

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel